| Code | CSB-RA006047MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Trabikibart, targeting CSF2RB (colony stimulating factor 2 receptor subunit beta), also known as the common beta chain (βc). CSF2RB is a shared receptor subunit critical for signaling by GM-CSF, IL-3, and IL-5 cytokines, playing essential roles in hematopoiesis, immune cell differentiation, and inflammatory responses. This receptor component is particularly important in myeloid cell development and function, and its dysregulation has been implicated in various inflammatory conditions, autoimmune disorders, and hematological malignancies. Aberrant CSF2RB signaling contributes to pathological inflammation in conditions such as rheumatoid arthritis and certain pulmonary disorders.
Trabikibart is a fully humanizedized monoclonal antibody targeting CSF2RB. It can bind to CSF2RB with high affinity, thereby simultaneously blocking IL-3, GM-CSF, and IL-5 mediated signaling pathways. This biosimilar antibody provides researchers with a valuable tool for investigating CSF2RB-dependent cellular mechanisms, cytokine receptor biology, and immune regulation. It supports studies examining the role of GM-CSF, IL-3, and IL-5 signaling in disease pathogenesis and enables exploration of therapeutic strategies targeting this receptor complex in inflammatory and immunological research models.
There are currently no reviews for this product.